Recent experimental findings suggest that simultaneous manipulation of the IL-33/ST2 and PD-1/PD-L1 signalling axes represents a potent strategy for enhancing antitumor immunity and controlling tumour progression [108,115]. This evidence concerns the gene PDCD1 and neoplasm.